Septegen Ltd was founded early in 2001, and will be the vehicle for the exploitation of the yeast-based screening systems developed by Professor John Davey. These screening systems will be invaluable in determining the function of new cell receptors identified by the Human Genome project, and could thus lead to the discovery of a variety of new types of pharmaceutical drug. The company expects to win its first contract, from a major UK pharmaceutical company, soon.
Neurosolutions Ltd was also founded early in 2001, and will use the expertise of Dave Spanswick, Kevin Lee and Dr Fei Yue to identify chemical compounds with significant effect on mammalian nervous systems. Such compounds could be the basis of new drugs for epilepsy, obesity, pain and other conditions. They have won their first contract from a major international pharmaceutical company, and will shortly be fitting out new laboratories.